17 reports

  • Gastrointestinal Drugs Market Trends And Strategies
  • Gastrointestinal Drugs Market Key Mergers And Acquisitions

The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors,...

  • Gastrointestinal Drug
  • World
  • Allergan plc
  • AstraZeneca PLC
  • Novo Nordisk Group
  • GASTROINTESTINAL DISORDERS, GLOBAL, KEY MARKETED PRODUCTS AND APPROVED INDICATIONS, 2016
  • Executive Summary

Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape Summary Gastrointestinal disorders are common, and a number of them have a large patient population. Across the seven major markets (the US, the UK, France,...

  • Gastrointestinal Drug
  • Pharmaceutical
  • Therapy
  • Market Size
  • AstraZeneca PLC
  • Impact of drivers and challenges

Safe if provided warnings are followed ##.

  • Gastrointestinal Drug
  • Market Size
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Digestive Remedies Market Overview

The demand for Bismuth preparation is limited due to its poor taste. (##)Sucralfate is an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

  • Gastrointestinal Drug
  • China
  • Demand
  • Trade
  • AstraZeneca PLC
  • CHAPTER IV DIGESTIVE REMEDIES DRUGS PRODUCTION AND DEMAND

The demand for Bismuth preparation is limited due to its poor taste. (##)Sucralfate is an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

  • Gastrointestinal Drug
  • Pharmaceutical
  • China
  • Demand
  • AstraZeneca PLC
  • Unaccomplished Trials of Reflux Esophagitis (Gastroesophageal Reflux Disease)
  • Five Key Clinical Profiles

Subjects were randomized in the ratio ##:## to one of the two arms.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Market Size
  • AstraZeneca PLC
  • Trial Results
  • ESOPHAGEAL DISEASES THERAPEUTICS, GLOBAL, TERMINATED CLINICAL TRIALS, 2015*

The prominent features of this report are - ##.

  • Clinical Trial
  • Gastrointestinal Drug
  • Therapy
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Clinical Trial Details
  • Contact Detail(s)

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics.

  • Gastrointestinal Drug
  • Pharmaceutical
  • China
  • Demand
  • AstraZeneca PLC

Drivers and their Impact Hospitals Low Low ## ## ## ## ## High High Impact on Key Customer Category Driver Low Pharmacies High ## ## ## ## ## Increase in Patient Population Improved Diagnosis Patient Assistance Programs ## ## ## ## ## Low Low ## ## ## ## ## High High ## ## ## ##

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Opioid
  • United States
  • AstraZeneca PLC

The usage of opioids and their adverse effects in gastrointestinal practice: a review.

  • Gastrointestinal Drug
  • Opioid
  • Therapy
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • AstraZeneca PLC
  • MAY 02, 2001: ASTRAZENECA RECEIVES SIX MONTHS' MARKET EXCLUSIVITY FOR PRILOSEC
  • OCT 20, 2000: JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC (OMEPRAZOLE) SAFETY AND EFFICACY

It is one of the top five pharmaceutical companies in the world with healthcare sales of over $##. ## billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • MAY 02, 2001: ASTRAZENECA RECEIVES SIX MONTHS' MARKET EXCLUSIVITY FOR PRILOSEC
  • OCT 20, 2000: JOINT FDA ADVISORY COMMITTEE CONFIRMS OTC PRILOSEC (OMEPRAZOLE) SAFETY AND EFFICACY

ASP-## is a selective COX ##(cyclooxygenases-##) inhibitor.

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • FEATURED NEWS & PRESS RELEASES
  • FEATURED NEWS & PRESS RELEASES

It is one of the world' s leading pharmaceutical companies with healthcare sales of $##. ## billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • AstraZeneca PLC

It is one of the world' s leading pharmaceutical companies with healthcare sales of $##. ## billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products.

  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • Product Initiative
  • AstraZeneca PLC